These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 35189334)
41. The correlation between the number of eligible patients in routine clinical practice and the low recruitment level in clinical trials: a retrospective study using electronic medical records. Sumi E; Teramukai S; Yamamoto K; Satoh M; Yamanaka K; Yokode M Trials; 2013 Dec; 14():426. PubMed ID: 24326039 [TBL] [Abstract][Full Text] [Related]
42. A Novel Patient Recruitment Strategy: Patient Selection Directly from the Community through Linkage to Clinical Data. Zimmerman LP; Goel S; Sathar S; Gladfelter CE; Onate A; Kane LL; Sital S; Phua J; Davis P; Margellos-Anast H; Meltzer DO; Polonsky TS; Shah RC; Trick WE; Ahmad FS; Kho AN Appl Clin Inform; 2018 Jan; 9(1):114-121. PubMed ID: 29444537 [TBL] [Abstract][Full Text] [Related]
43. Success and failure factors of patient recruitment for industry-sponsored clinical trials and the role of the electronic health records-a qualitative interview study in the Nordic countries. Laaksonen N; Bengtström M; Axelin A; Blomster J; Scheinin M; Huupponen R Trials; 2022 May; 23(1):385. PubMed ID: 35550003 [TBL] [Abstract][Full Text] [Related]
44. Automatic trial eligibility surveillance based on unstructured clinical data. Meystre SM; Heider PM; Kim Y; Aruch DB; Britten CD Int J Med Inform; 2019 Sep; 129():13-19. PubMed ID: 31445247 [TBL] [Abstract][Full Text] [Related]
45. ClinicalTrials.gov as a data source for semi-automated point-of-care trial eligibility screening. Pfiffner PB; Oh J; Miller TA; Mandl KD PLoS One; 2014; 9(10):e111055. PubMed ID: 25334031 [TBL] [Abstract][Full Text] [Related]
46. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
47. Comparison of electronic health record system functionalities to support the patient recruitment process in clinical trials. Schreiweis B; Trinczek B; Köpcke F; Leusch T; Majeed RW; Wenk J; Bergh B; Ohmann C; Röhrig R; Dugas M; Prokosch HU Int J Med Inform; 2014 Nov; 83(11):860-8. PubMed ID: 25189709 [TBL] [Abstract][Full Text] [Related]
48. A Framework for Systematic Assessment of Clinical Trial Population Representativeness Using Electronic Health Records Data. Sun Y; Butler A; Diallo I; Kim JH; Ta C; Rogers JR; Liu H; Weng C Appl Clin Inform; 2021 Aug; 12(4):816-825. PubMed ID: 34496418 [TBL] [Abstract][Full Text] [Related]
49. Evaluating eligibility criteria of oncology trials using real-world data and AI. Liu R; Rizzo S; Whipple S; Pal N; Pineda AL; Lu M; Arnieri B; Lu Y; Capra W; Copping R; Zou J Nature; 2021 Apr; 592(7855):629-633. PubMed ID: 33828294 [TBL] [Abstract][Full Text] [Related]
50. Impact of electronic health records on predefined safety outcomes in patients admitted to hospital: a scoping review. Subbe CP; Tellier G; Barach P BMJ Open; 2021 Jan; 11(1):e047446. PubMed ID: 33441368 [TBL] [Abstract][Full Text] [Related]
51. A European inventory of common electronic health record data elements for clinical trial feasibility. Doods J; Botteri F; Dugas M; Fritz F; Trials; 2014 Jan; 15():18. PubMed ID: 24410735 [TBL] [Abstract][Full Text] [Related]
52. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601 [TBL] [Abstract][Full Text] [Related]
53. Assessing an Electronic Health Record research platform for identification of clinical trial participants. Laaksonen N; Varjonen JM; Blomster M; Palomäki A; Vasankari T; Airaksinen J; Huupponen R; Scheinin M; Juuso Blomster Contemp Clin Trials Commun; 2021 Mar; 21():100692. PubMed ID: 33409423 [TBL] [Abstract][Full Text] [Related]
54. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933 [TBL] [Abstract][Full Text] [Related]
55. Pharmacological interventions for heart failure in people with chronic kidney disease. Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487 [TBL] [Abstract][Full Text] [Related]
56. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671 [TBL] [Abstract][Full Text] [Related]
57. Development of Patient Databases for Endocrinological Clinical and Pharmaceutical Trials: A Survey. Vezertzis K; Lambrou GI; Koutsouris D Rev Recent Clin Trials; 2020; 15(1):5-21. PubMed ID: 31744453 [TBL] [Abstract][Full Text] [Related]
58. IDENTIFYING GENETIC ASSOCIATIONS WITH VARIABILITY IN METABOLIC HEALTH AND BLOOD COUNT LABORATORY VALUES: DIVING INTO THE QUANTITATIVE TRAITS BY LEVERAGING LONGITUDINAL DATA FROM AN EHR. Verma SS; Lucas AM; Lavage DR; Leader JB; Metpally R; Krishnamurthy S; Dewey F; Borecki I; Lopez A; Overton J; Penn J; Reid J; Pendergrass SA; Breitwieser G; Ritchie MD Pac Symp Biocomput; 2017; 22():533-544. PubMed ID: 27897004 [TBL] [Abstract][Full Text] [Related]
59. Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. Ahmad FS; Ricket IM; Hammill BG; Eskenazi L; Robertson HR; Curtis LH; Dobi CD; Girotra S; Haynes K; Kizer JR; Kripalani S; Roe MT; Roumie CL; Waitman R; Jones WS; Weiner MG Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006292. PubMed ID: 32466729 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]